The study represents the first comprehensive in silico drug-target prioritisation for T. foetus in roughly a decade. The previous analysis, published ten years ago, proposed 113 candidate targets based solely on homology to compounds catalogued in the ChEMBL database. Since then, both the genomic resources available for the parasite and the pharmacological landscape have changed considerably. The new work, led by Joanna Dąbrowska with colleagues Maciej Kochanowski and Jacek Sroka, set out to close that gap with a far more layered approach, drawing on multiple independent lines of evidence rather than a single homology filter.

The pipeline began with the predicted proteome of T. foetus strain K, which contains 25,030 proteins. From this starting point, the researchers applied a subtractive strategy designed to strip away anything unlikely to make a safe and effective drug target. Proteins with close counterparts in the feline host were filtered out, reducing the risk that an inhibitor would also attack the cat’s own biology. The remaining proteins were then cross-referenced against three pharmacological reference databases, which flag targets already known to be druggable, and against essential-gene resources drawn from three model eukaryotic organisms, which highlight genes that parasites of this kind cannot survive without.

A further layer of prioritisation drew on PHI-base, a curated virulence reference database that catalogues genes experimentally shown to contribute to pathogenicity in other organisms. Proteins appearing in this resource are attractive candidates because disrupting them could blunt the parasite’s ability to cause disease, not merely its survival in culture. When all of these filters were combined, the pipeline returned 433 priority candidates from strain K. To test whether the result was an artefact of one particular genome assembly, the team ran the identical pipeline on a chromosome-scale assembly of a second strain, KV-1, which yielded 436 candidates. Sixty-six percent of the candidates were recovered as reciprocal best hits between the two strains, a substantial cross-strain overlap that strengthens confidence in the robustness of the target list.

Expression data added a third dimension to the prioritisation. A candidate protein may look perfect on paper, but if the gene encoding it is silent in the disease-relevant life stage, it offers little therapeutic purchase. Using gene-level transcriptomic data from the feline isolate G10/1, the researchers found that 82.7 percent of the priority candidates were actively transcribed in that isolate, measured in transcripts per million. This high proportion of expressed targets suggests that the subtractive pipeline is not merely cataloguing genomic relics but is surfacing proteins the parasite genuinely deploys during infection of its feline host.

The most striking finding emerged when the candidates were ranked by expression level. Nine of the ten most highly expressed priority candidates belong to protein families for which clinically advanced small-molecule inhibitors are already available. These families include the molecular chaperones Hsp70 and Hsp90, the CDC48/p97 AAA+ ATPase, components of the ubiquitin-proteasome pathway, and serine/threonine kinases. Each of these protein classes has been the subject of intensive pharmaceutical development in human medicine, particularly in oncology, where inhibitors of Hsp90, p97, the proteasome, and various kinases have advanced through clinical trials or reached approval. The implication is direct: medicinal chemistry against these families is mature, and existing compounds or close analogues could be screened for activity against T. foetus without the need to invent inhibitor scaffolds from scratch.

The tenth member of that top-ten list stands out for a different reason. It is a Rab4B GTPase, a member of the broader Ras/GTPase superfamily, which is generally considered pharmacologically tractable because GTP-binding proteins have well-defined nucleotide pockets that small molecules can target. However, no Rab4B-specific inhibitor has been characterised to date. This makes the Rab4B candidate both an intriguing opportunity and an open challenge: it would require de novo inhibitor development rather than repurposing, but it sits within a protein superfamily with a long track record of successful drug discovery.

To demonstrate that the candidate list can support structure-based work, the team carried out a proof-of-concept molecular docking screen against three of the top-ranked candidates. Docking computationally fits small ligands into the three-dimensional structures of target proteins and scores the predicted binding affinity. Using a ligand library that included positive controls, negative control analogues, selective inhibitors, and natural ligand controls, each annotated with its clinical or pre-clinical development status, the researchers recovered internally consistent, structure-based affinity rankings across the three targets. The authors are careful to note that these computational results await experimental validation, but the internal consistency of the rankings suggests the protein structures and docking workflow are behaving as expected and can serve as a foundation for laboratory follow-up.

The practical significance of the work lies in the disease it addresses. Feline tritrichomonosis is a chronic large-bowel diarrhoea that persists in infected cats, and with no approved therapy, veterinarians are left using ronidazole off-label. The drug’s narrow therapeutic window means the margin between an effective dose and a toxic one is slim, and the documented spread of resistance across three continents makes the search for alternatives urgent. By identifying targets in protein families with existing clinical-grade inhibitors, the study offers what the authors describe as an immediate opportunity for drug-repurposing studies. Repurposing, in which drugs developed for one indication are tested against another, can compress the timeline and cost of drug development dramatically, because safety, pharmacokinetic, and manufacturing data for the original compounds may already exist.

The researchers have made their full candidate list and supporting data openly available as supplementary tables, including UniProt and RefSeq identifiers, locus tags, protein descriptions, Pfam and InterPro annotations, Gene Ontology terms, pathway counts, expression values, the complete docking ligand library, and the cross-strain reciprocal best hit pairs. The work was supported by the Internal Research Fund of the National Veterinary Research Institute under project F/123, and the authors acknowledge the Galaxy Europe community and the European Bioinformatics Institute for maintaining the public bioinformatic resources on which the analysis relied, including Ensembl Protists, InterProScan, and the AlphaFold Protein Structure Database. For a parasite that has received far less research attention than its importance to feline health would justify, the study provides both a starting point for experimental target validation and a template for how integrative omics can accelerate drug discovery in neglected veterinary pathogens.

Subject of Research: Integrative omics identification of drug-repurposing targets in the feline parasite Tritrichomonas foetus

Article Title: Integrative omics reveals candidate drug-repurposing targets in Tritrichomonas foetus

Article References: Dąbrowska, J., Kochanowski, M., & Sroka, J. (2026). Integrative omics reveals candidate drug-repurposing targets in Tritrichomonas foetus. BMC Genomics. https://doi.org/10.1186/s12864-026-13330-5

Image Credits: AI Generated

DOI: 10.1186/s12864-026-13330-5

Keywords: Tritrichomonas foetus, feline tritrichomonosis, drug repurposing, drug-target prioritisation, subtractive proteomics, comparative genomics, molecular docking, Hsp90, ubiquitin-proteasome pathway, kinases, Rab4B GTPase, ronidazole resistance

To understand why the discovery matters, it helps to start with the biology of protein turnover. Inside every cell, proteins that are damaged, misfolded or simply no longer needed are tagged with small molecules called ubiquitin, a molecular label that condemns them to destruction by the proteasome, the cell’s waste-disposal complex. Deubiquitinating enzymes, or DUBs, do the opposite: they snip ubiquitin tags off proteins, rescuing them from degradation and extending their functional lifespan. When this balancing act goes wrong, proteins that should be cleared can accumulate to abnormal levels, and in cancer that often means proteins that drive uncontrolled growth are granted an unnatural stay of execution. USP12 belongs to the ubiquitin-specific protease family, and previous work has linked it to several cancers, but its role in ovarian cancer had remained poorly defined.

The identity of its partner in this study was equally obscure. TBC1D22A is a member of the TBC1 domain family, proteins that act as GTPase-activating proteins for Rab GTPases, the molecular switches that regulate vesicle trafficking, membrane trafficking and intracellular transport. While Rab proteins have increasingly been implicated in tumor progression, TBC1D22A’s specific oncogenic mechanisms in ovarian cancer, and crucially the upstream pathways that regulate it, had never been reported. The new study set out to fill that gap by asking a deceptively simple question: what keeps TBC1D22A stable inside ovarian cancer cells, and what happens when that stability is disrupted?

The answer emerged from an unbiased hunt for TBC1D22A’s molecular companions. Using liquid chromatography coupled with tandem mass spectrometry, or LC-MS/MS, the researchers screened for proteins that physically associate with TBC1D22A, and USP12 surfaced as a candidate interacting deubiquitinase. The team then confirmed the partnership through complementary techniques: co-immunoprecipitation experiments showed that the two proteins can be pulled down together from cell lysates, while immunofluorescence co-localization assays revealed that they occupy overlapping territories within the cell. Together, these approaches established that the association is not a fleeting accident of cellular crowding but a genuine physical interaction, the kind that can support a regulatory relationship.

With the interaction confirmed, the researchers moved on to the central mechanistic question: does USP12 actually control how much TBC1D22A exists inside a cell, and if so, how? The evidence points firmly to post-translational regulation. Cycloheximide chase experiments, which block new protein synthesis and allow researchers to watch existing proteins decay over time, showed that TBC1D22A degraded more slowly when USP12 was present. Proteasome inhibition assays demonstrated that TBC1D22A’s destruction proceeds through the ubiquitin-proteasome pathway. Most tellingly, in vivo ubiquitination assays revealed that USP12 directly reduces the ubiquitin load carried by TBC1D22A, effectively stripping off the degradation tags before the proteasome can act. Importantly, USP12 did not alter TBC1D22A transcription, meaning the enzyme works purely at the protein level, preserving existing TBC1D22A molecules rather than coaxing the gene to make more.

That stabilization has consequences. Through a series of gain-of-function and loss-of-function experiments, the team showed that USP12 promotes ovarian cancer cell proliferation, migration and invasion, and that these effects depend on TBC1D22A. When the researchers removed USP12, TBC1D22A levels fell and the cancer cells became less motile and less invasive; when they re-introduced TBC1D22A in rescue experiments, the aggressive behavior returned. This dependency is the crucial detail: it means USP12 is not simply a general growth promoter acting through many parallel routes, but a specific upstream regulator whose oncogenic influence flows through TBC1D22A. Depleting the downstream partner effectively neutralizes the upstream enzyme, which is exactly the kind of linear dependency that makes a signaling axis attractive as a drug target.

The signaling pathway connecting the pair to malignancy is one of the most famous in all of cancer biology. The PI3K-AKT-mTOR cascade integrates signals from growth factor receptors and relays them to the cell’s growth and survival machinery, promoting metabolism, protein synthesis, proliferation and resistance to cell death. It is hyperactivated in a large fraction of human tumors, including ovarian cancers, and has been the subject of intense pharmaceutical interest for decades. In this study, the USP12-TBC1D22A axis was associated with activation of this pathway, providing a plausible mechanistic bridge between a vesicle-trafficking regulator and the malignant phenotype. The researchers also validated their findings in vivo using subcutaneous xenograft models, in which manipulated ovarian cancer cells were grown as tumors in animals, confirming that the axis influences tumor growth outside the controlled environment of a culture dish.

The clinical data add a layer of real-world relevance. Transcriptomic analysis, tissue microarrays and data from The Cancer Genome Atlas cohorts showed that USP12 is upregulated in ovarian cancer tissues compared with normal tissue, and that its expression positively correlates with TBC1D22A levels, consistent with the stabilizing relationship uncovered in the lab. More ominously, high USP12 expression predicted poorer overall survival and poorer progression-free survival in patients. In other words, the same molecular relationship that drives aggressiveness in laboratory models also tracks with worse outcomes in the clinic, strengthening the case that the axis is not an artifact of experimental conditions but a genuine feature of the disease.

For patients, the implications are cautiously encouraging. Ovarian cancer is often treated with surgery and platinum-based chemotherapy, and while PARP inhibitors have improved outlooks for some patients with homologous recombination deficiency, many tumors eventually become resistant. A deubiquitinase such as USP12 represents a different class of target, and DUB inhibitors have become an active frontier in drug development precisely because these enzymes can be drugged in ways that stabilize-or destabilize-key disease proteins. If the USP12-TBC1D22A axis proves essential in a broader set of ovarian tumors, blocking USP12 could deprive cancer cells of their stabilized TBC1D22A supply and dampen PI3K-AKT-mTOR signaling, potentially complementing existing therapies. The correlation between USP12 and survival also suggests it could serve as a prognostic marker, helping clinicians identify patients whose disease is likely to progress more rapidly.

There are, of course, important caveats. The study relied on cell lines, xenograft models and retrospective analysis of patient cohorts; prospective clinical validation, and demonstration that pharmacologically inhibiting USP12 benefits patients, remain future work. DUBs often have multiple substrates, so any therapeutic strategy would need to account for effects beyond TBC1D22A. Still, the work fills a genuine gap by identifying the first reported upstream regulatory pathway for TBC1D22A in ovarian cancer, and it does so with a methodologically thorough chain of evidence, from unbiased mass spectrometry through mechanistic biochemistry to animal models and human tissue data. As the authors conclude, the USP12-TBC1D22A axis may serve as a promising therapeutic target for ovarian cancer, and for a disease where new molecular handles are scarce, that promise is worth taking seriously.

Subject of Research: USP12-mediated deubiquitination and stabilization of TBC1D22A in ovarian cancer progression

Article Title: USP12 stabilizes TBC1D22A via deubiquitination to activate PI3K-AKT-mTOR signaling and promote ovarian cancer progression

Article References: Lv, X., Gong, R., Cai, X., & Guo, R. (2026). USP12 stabilizes TBC1D22A via deubiquitination to activate PI3K-AKT-mTOR signaling and promote ovarian cancer progression. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09027-8

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09027-8

Keywords: USP12, TBC1D22A, ovarian cancer, deubiquitinase, ubiquitin-proteasome pathway, PI3K-AKT-mTOR signaling, protein stability, Rab GTPase-activating protein, prognostic biomarker, xenograft model, Journal of Translational Medicine, cancer signaling

The research, led by Chenxi Li, Yingying Qin and Yajuan Yang of Shandong University and collaborating institutions in China, focused on what happens when mouse primordial germ cells lose RAD54 like, or RAD54L. The team found that without this factor, the cells proliferate poorly, leaving an insufficient pool of germ cells and ultimately impairing fertility. The defect traces back to a specific molecular hazard: the accumulation of topoisomerase I cleavage complexes, abbreviated TOP1ccs, which are among the most common and most dangerous lesions that arise during DNA replication.

To appreciate why TOP1ccs matter, it helps to understand what topoisomerase I normally does. As the two strands of the double helix are prised apart for copying, the DNA ahead of the replication machinery becomes overwound, like a rope twisted too tightly. Topoisomerase I relieves this torsional stress by nicking one strand of the DNA, allowing it to swivel freely, and then sealing the break again. The enzyme normally completes this cut-and-paste cycle in a fraction of a second. Occasionally, however, the enzyme becomes trapped mid-cycle, covalently bonded to the DNA at the nick it just created. That trapped enzyme-DNA adduct is the TOP1 cleavage complex, and if it is not removed promptly, the approaching replication fork collides with it, converting a transient intermediate into a double-strand break and stalling DNA synthesis.

Cells possess dedicated machinery to clear these protein-DNA adducts, and the new study adds a surprising player to that list. The researchers showed that RAD54L promotes the degradation of TOP1ccs through the ubiquitin-proteasome pathway, the cellular recycling system that tags unwanted proteins with chains of ubiquitin and delivers them to the proteasome for destruction. The key to this activity lies in a partnership between RAD54L and tripartite motif-containing protein 21, or TRIM21, which the authors identify as a newly recognized E3 ubiquitin ligase responsible for clearing TOP1ccs. E3 ligases are the enzymes that confer specificity on the ubiquitin system, deciding which targets get marked for degradation. In this case, TRIM21 appears to be the enzyme that flags trapped topoisomerase I for removal.

The mechanistic twist is that RAD54L does not itself ligate ubiquitin. Instead, it interacts with TRIM21 and stabilizes the protein, keeping sufficient TRIM21 available to do its clearing work. When RAD54L is absent, TRIM21 is not maintained properly, TOP1ccs accumulate, and the resulting DNA damage escalates. In RAD54L-deficient primordial germ cells, this cascade of events exacerbates DNA damage, undermines proliferation and erodes the reproductive reserve. The finding reframes RAD54L, historically viewed as a homologous recombination factor that helps search for and invade homologous DNA templates during double-strand break repair, as also acting upstream of repair, at the stage of removing the lesions that would otherwise create breaks in the first place.

Primordial germ cells are an especially revealing setting for this kind of analysis. These cells undergo rapid mitotic divisions during embryonic development, and their genome must be transmitted faithfully across generations. High levels of replication, combined with the metabolic demands of a growing embryo, make TOP1ccs a constant threat. The DNA damage response mechanisms that protect somatic cells have been studied extensively, but the regulatory networks that safeguard the germline during this early mitotic phase have remained largely unexplored. By showing that a defect in a single DNA damage response factor can compromise the founding population of the germline, the study connects genome maintenance at the molecular level to fertility at the organismal level.

The experimental logic of the work follows a path familiar to genome stability researchers but with distinctive results. Mice lacking RAD54L in their germ cells show proliferation defects in the primordial germ cell population. The DNA damage observed in these cells is not random; it is specifically tied to TOP1cc accumulation, which means the damage is preventable if the trapped complexes are cleared. The demonstration that RAD54L stabilizes TRIM21 provides a coherent causal chain: loss of RAD54L destabilizes the E3 ligase, the ligase can no longer ubiquitinate trapped topoisomerase I efficiently, the adducts persist, replication forks collide with them, and DNA damage mounts until cells falter or die.

The discovery also resonates with a broader and clinically important theme in cancer medicine. Drugs called topoisomerase I poisons, including camptothecin and its clinical derivatives irinotecan and topotecan, work precisely by stabilizing the TOP1 cleavage complex, trapping the enzyme on DNA and forcing tumor cells into lethal collisions between replication forks and the drug-stabilized adducts. Understanding how healthy cells, and particularly vulnerable populations like germ cells, clear TOP1ccs has implications for how such treatments affect fertility and for how resistance to these drugs emerges. A pathway involving RAD54L and TRIM21 that governs the lifespan of TOP1ccs could, in principle, influence both the toxicity and the efficacy of these widely used chemotherapeutics, although the new study addresses physiology rather than treatment outcomes.

TRIM21 itself carries an interesting scientific history. Long studied in immunology as an antibody receptor inside cells, it has more recently been appreciated as a versatile quality-control factor that recognizes and ubiquitinates a range of intracellular targets. Its identification here as the E3 ligase for TOP1cc clearance in germ cells extends that repertoire into genome maintenance and adds a new dimension to how the ubiquitin system participates in the DNA damage response. The RAD54L-TRIM21 axis suggests that repair factors may do more than mend breaks after they occur; some may actively manage the burden of endogenous lesions so that breaks are less likely to arise at all.

For the field of reproductive biology, the study fills in a piece of a larger puzzle: how the mitotic phase of gametogenesis, before meiosis begins, is protected against the wear and tear of rapid proliferation. The authors frame their results as extending understanding of the regulatory mechanisms that safeguard genome integrity during this process, and the practical significance is clear. A diminished primordial germ cell pool is a diminished reproductive reserve, and the work points to TOP1cc accumulation as one preventable driver of that loss. As with any mouse study, translating the findings to human fertility will require further work, but the core machinery of topoisomerase I, the ubiquitin-proteasome system and the DNA damage response is conserved across mammals, making the pathway a plausible target for future investigations into reproductive health and the side effects of topoisomerase-targeting therapies.

Subject of Research: The role of RAD54L and TRIM21 in clearing topoisomerase I cleavage complexes to maintain genome stability in primordial germ cells

Article Title: RAD54L counteracts topoisomerase I cleavage complexes by stabilizing E3 ligase TRIM21 to maintain genome stability

Article References: Li, C., Wang, S., Xu, W., Kong, Z., Wen, C., Zhao, S., Cao, L., Chen, Z.-J., Zhao, S., Qin, Y., & Yang, Y. (2026). RAD54L counteracts topoisomerase I cleavage complexes by stabilizing E3 ligase TRIM21 to maintain genome stability. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06458-w

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06458-w

Keywords: RAD54L, TRIM21, topoisomerase I cleavage complexes, primordial germ cells, genome stability, DNA damage response, ubiquitin-proteasome pathway, replication stress, fertility, gametogenesis, E3 ubiquitin ligase, DNA repair

Chronic hepatitis B remains one of medicine’s most intractable problems. Hundreds of millions of people worldwide carry the virus long-term, and in a substantial fraction of them the infection silently progresses toward cirrhosis and hepatocellular carcinoma, claiming hundreds of thousands of lives each year. Current antivirals — nucleoside and nucleotide analogues such as entecavir and tenofovir — potently suppress viral replication but almost never eradicate it, because HBV archives its genetic blueprint as covalently closed circular DNA in the nuclei of hepatocytes, a reservoir that these drugs cannot touch. Pegylated interferon-alpha, the other mainstay therapy, achieves durable control in only a minority of patients. Interferon-based regimens depend on coaxing the infected cell’s own antiviral genes into action, which is precisely why interferon-stimulated genes have become a hunting ground for new therapeutic targets. A “functional cure,” in which the immune system holds the virus in check without ongoing treatment, is widely regarded as the field’s ultimate goal, and that ambition has pushed researchers toward host-directed strategies that reprogram the infected cell itself.

The new study began with a clinical observation. The researchers collected serum samples from 208 patients with chronic hepatitis B and examined lactate dehydrogenase, or LDH, an enzyme that spills into the bloodstream when cells are damaged or metabolically revved up. Serum LDH levels correlated positively with both HBV viral load and standard markers of liver injury, including alanine aminotransferase and aspartate aminotransferase. LDH activity is a routine measurement in clinical chemistry, and its elevation in chronic hepatitis B has long been read as a nonspecific sign of hepatocyte damage; the new data suggest it also carries metabolic information that tracks viral activity far more directly. In other words, the more actively the virus replicated, the hotter the patients’ lactate metabolism appeared to run — a correlation consistent with the idea that HBV co-opts the glycolytic machinery of hepatocytes to fuel its own replication. Earlier work had already implicated LDHA, the subunit responsible for converting pyruvate into lactate, in promoting HBV replication. What remained missing was a regulatory mechanism: what, inside an infected liver, decides how much LDHA the virus gets to keep?

The Fujian team turned to TRIM22, a member of the tripartite motif family of proteins and a well-characterized interferon-stimulated gene. TRIM22 carries a RING domain, a catalytic module that allows it to function as an E3 ubiquitin ligase — the class of enzymes that, working with ubiquitin-activating E1 and ubiquitin-conjugating E2 enzymes, attaches ubiquitin tags to specific substrates and thereby decides their fate. Although TRIM22 has long been associated with antiviral defense, whether its ligase activity had anything to do with HBV, and whether that activity might intersect with cellular metabolism, was unknown. The first clue came from the public gene-expression dataset GSE65359, derived from liver tissue of patients with chronic hepatitis B: TRIM22 expression was negatively correlated with LDHA and with the lactate transporters SLC16A1 and SLC16A4, the membrane channels that export lactate from cells. The inverse relationship hinted that TRIM22 might act as a physiological brake on the very glycolytic program that HBV prefers.

To test that idea, the researchers established TRIM22-overexpressing cell models and interrogated them with transcriptomic sequencing, targeted metabolomics and Seahorse extracellular acidification rate (ECAR) analysis, a technique that measures real-time acid efflux as a live readout of glycolytic activity. The results were strikingly coherent. Overexpression of TRIM22 dampened glycolytic gene expression, shifted the metabolite landscape away from glycolytic intermediates, and measurably reduced ECAR, confirming that glycolytic flux itself — not merely the transcriptomic signature — had been suppressed. Targeted metabolomics reinforced the picture, revealing shifts in central carbon metabolites consistent with a slowdown of glycolysis. At the same time, the cells displayed signs of a reinvigorated tricarboxylic acid cycle, suggesting that pyruvate was being funneled back into mitochondrial respiration instead of being fermented to lactate. Transcriptomic comparisons pointed the same way, with glycolysis-linked genes sliding downward while immune signaling modules gained ground. Functionally, this metabolic rewiring carried an antiviral dividend: HBV replication markers fell in the TRIM22-enhanced cells.

The next question was mechanistic: how does TRIM22 reach into the glycolytic pathway at all? Using co-immunoprecipitation coupled to liquid chromatography–tandem mass spectrometry (LC-MS/MS), the team screened for proteins that physically associate with TRIM22 and identified LDHA as a novel interacting partner. Domain-mapping experiments with deletion mutants then pinpointed the anatomy of the interaction: TRIM22’s coiled-coil domain mediates the physical handshake with LDHA, while its RING domain catalyzes the attachment of K48-linked polyubiquitin chains to the enzyme. The linkage type matters enormously. K48 chains are the proteasome’s shipping label, directing the tagged protein to the proteasome for demolition, whereas K63 chains typically serve as signaling scaffolds. When the researchers blocked the proteasome with MG132, LDHA was rescued from TRIM22-driven degradation, sealing the case that TRIM22 functions as a bona fide E3 ligase for this glycolytic enzyme.

Destroying LDHA, it turned out, does far more than starve the virus; it unmutes innate immune signaling. In cells where TRIM22 degraded LDHA, the researchers documented enhanced activation of the retinoic acid-inducible gene I (RIG-I)–mitochondrial antiviral signaling protein (MAVS) pathway, the frontline sensor circuit for viral RNA. In this cascade, RIG-I recognizes foreign RNA and recruits MAVS on the outer mitochondrial membrane, which in turn activates TANK-binding kinase 1 (TBK1); phosphorylated TBK1 then phosphorylates interferon regulatory factor 3 (IRF3), which enters the nucleus and switches on interferon-beta and a battery of interferon-stimulated genes. The revival of this pathway matters because HBV, although formally a DNA virus, transcribes its genome through RNA intermediates, giving RNA sensors a legitimate molecular target at multiple points in its life cycle. That sequence ran measurably hotter when LDHA was removed, and HBV markers — hepatitis B surface antigen, e antigen, core antigen and viral DNA — declined in parallel. The study thereby connects a metabolic enzyme to an immune checkpoint: as long as LDHA remains abundant, the alarm stays muffled; when TRIM22 clears LDHA, the alarm switches on.

The team then ran the logic in reverse. When LDHA was overexpressed, HBV replication climbed and the RIG-I-MAVS pathway was measurably suppressed. Transcriptomic analysis traced part of this immunosuppressive effect to the downregulation of two chemokine genes, CCL3L1 and CCL24, which the authors propose may act as intermediaries between glycolytic activity and antiviral signaling; chemokines of this kind help orchestrate the recruitment and positioning of antiviral immune cells, so their loss offers a plausible route by which a metabolic enzyme could quietly damp the body’s defenses. Functional rescue experiments cemented the causal chain: co-transfecting cells with LDHA partially restored viral replication even in the presence of TRIM22, and treatment with amlexanox, an approved anti-inflammatory drug frequently used to probe the TBK1–IRF3 axis, was deployed to test the pathway’s contribution. Together, the gain-of-function and loss-of-function data establish that LDHA is not a passive bystander in HBV infection but an active suppressor of innate immunity whose presence the virus exploits.

The therapeutic implications are layered. The work supplies a mechanistic rationale for LDHA inhibitors as host-directed anti-HBV agents — a class of compounds already under development in oncology, where tumor cells’ addiction to aerobic glycolysis has made LDHA a drug target in its own right. It also highlights the appeal of engineered degradation strategies: proteolysis-targeting chimeras, or PROTACs, co-opt the cell’s own ubiquitin-proteasome system to destroy disease-relevant proteins, and the TRIM22–LDHA axis shows that removing LDHA would pay a double dividend, cutting the virus’s fuel supply while disinhibiting innate immunity. The findings may also illuminate why interferon therapy works at all: interferon potently induces TRIM22, so part of its antiviral effect could plausibly flow through this newly described ubiquitination circuit. And because the mechanism is enzymatic and structurally defined — a RING domain acting on a named substrate — it hands medicinal chemists a concrete blueprint rather than a loose correlation.

The authors are appropriately cautious about the distance between culture dish and clinic. The mechanistic work rests on overexpression models, domain-deletion mutants and pharmacologic probes, supported by clinical correlation in patient sera, and the paper was released early as a citable, peer-reviewed accepted manuscript whose final version of record is still pending minor editorial edits. Clinical translation will require showing that pharmacologically lowering LDHA — or boosting TRIM22 — in genuinely infected livers suppresses HBV without unacceptable toxicity, a nontrivial demand given that LDHA is central to energy metabolism in muscle and red blood cells. Even so, the study defines a clean, testable mechanism: an interferon-stimulated E3 ligase ubiquitinates a glycolytic enzyme through its RING domain, weakening the virus’s metabolic supply line while amplifying the RIG-I-MAVS alarm. For a virus that has outmaneuvered direct-acting drugs for decades, an attack on its fuel — and on its silencing grip over the immune system — opens an inviting new flank. The work was supported in part by the National Natural Science Foundation of China and Fujian provincial research programs.